1. In vivogenetic screen identifies a SLC5A3-dependent myo-inositol auxotrophy in acute myeloid leukemia
- Author
-
Christopher R. Vakoc, Sofya A. Polyanskaya, Olaf Klingbeil, Kenneth Chang, Melissa Kramer, Sara Goodwin, W. R. McCombie, Emily Hodges, Maria E. Figueroa, Emmalee R. Adelman, Zhaolin Yang, Shruti V. Iyer, Sofia Costa, Yiliang Wei, and Osama El Demerdash
- Subjects
Auxotrophy ,CEBPA ,Cancer cell ,Cancer research ,Gene silencing ,Myeloid leukemia ,Synthetic lethality ,Biology ,Genetic screen ,Solute carrier family - Abstract
An enhanced requirement for extracellular nutrients is a hallmark property of cancer cells. Here, we optimized anin vivogenetic screening strategy for evaluating dependencies in acute myeloid leukemia (AML), which led to the identification of the myo-inositol transporter SLC5A3 as a unique vulnerability in this disease. In accord with this transport function, we demonstrate that the SLC5A3 dependency reflects a myo-inositol auxotrophy in AML. Importantly, the commonality among SLC5A3-dependent AML lines is the transcriptional silencing ofISYNA1, which encodes the rate limiting enzyme for myoinositol biosynthesis, inositol-3-phosphate synthase 1. We used gain- and loss-of-function experiments to demonstrate a synthetic lethal genetic interaction betweenISYNA1andSLC5A3in AML, which function redundantly to sustain intracellular myo-inositol. Transcriptional silencing and DNA hypermethylation ofISYNA1occur in a recurrent manner in human AML patient samples, in association with the presence ofIDH1/IDH2andCEBPAmutations. Collectively, our findings reveal myo-inositol auxotrophy as a novel form of metabolic dysregulation in AML, which is caused by the aberrant silencing of a biosynthetic enzyme.Statement of significanceHere, we show how epigenetic silencing can provoke a nutrient dependency in AML by exploiting a synthetic lethality relationship between biosynthesis and transport of myo-inositol. Blocking the function of this solute carrier may have therapeutic potential in an epigenetically-defined subset of AML.
- Published
- 2020
- Full Text
- View/download PDF